O-22 METABOLIC ASSOCIATED FATTY LIVER DISEASE: A SEVERE LIVER DISEASE

Abstract

The spectrum of metabolic associated fatty liver disease (MAFLD) includes steatosis, steatohepatitis, that can progress to cirrhosis, hepatocellular carcinoma, and to advanced stage of liver disease. MAFLD associated with hepatic insufficiency has been frequent in the clinical practice. To evaluate the frequency and characteristics of MAFLD patients with advanced liver disease. The case-series included MAFLD patients with advanced disease come from at a hepatology clinic. MAFLD criteria: past or present evidence of metabolic risk factors; presence or previous documentation of steatosis by imaging or histological analysis. Child-Pugh and MELD scores were used to estimate MAFLD prognosis. Portal hypertension (PH) was defined by the presence of gastro-esophageal varices on endoscopy. The data were collected and analyzed using the statistic program SPSS. A total of 263 patients with MAFLD were included; 48 (18.25%) presented advanced liver disease. Most were female (79.2%); 68.8% were of African descent; median age was 69 years (IIQ 59.75-76.50). Features of metabolic syndrome was frequent in these patients (60.4% presented arterial hypertension; 47.9% diabetes, and 1% dyslipidemia). Child-Pugh (C-P) A was observed in 24.4% of the cases; C-P B in 63.4%; C-P C in 12.2%. MELD scores ranged from 7-24 (mean 13.34). PH was observed in 60.41% of the cases. In a large series of patients with MAFLD, the frequency of hepatic insufficiency and portal hypertension were significant. Relevant finding in this simple also was the predominance of African descent individuals, who usually have a better MAFLD prognosis. This result needs to be better evaluated.